<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719112452941</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719112452941</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ozer</surname>
<given-names>Hatice</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1933719112452941">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boztosun</surname>
<given-names>Abdullah</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1933719112452941">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Açmaz</surname>
<given-names>Gökhan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1933719112452941">3</xref>
<xref ref-type="corresp" rid="corresp1-1933719112452941"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Atılgan</surname>
<given-names>Remzi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-1933719112452941">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akkar</surname>
<given-names>Ozlem Bozoklu</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1933719112452941">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kosar</surname>
<given-names>Mehmet Ilkay</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-1933719112452941">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-1933719112452941">
<label>1</label>Department of Pathology, Cumhuriyet University School of Medicine, Sivas, Turkey</aff>
<aff id="aff2-1933719112452941">
<label>2</label>Department of Obstetrics and Gynecology, Cumhuriyet University School of Medicine, Sivas, Turkey</aff>
<aff id="aff3-1933719112452941">
<label>3</label>Department of Obstetrics and Gynecology, Kayseri Training and Education Hospital of Medicine, Kayseri, Turkey</aff>
<aff id="aff4-1933719112452941">
<label>4</label>Department of Obstetrics and Gynecology, Fırat University School of Medicine, Elazığ, Turkey</aff>
<aff id="aff5-1933719112452941">
<label>5</label>Department of Anatomy, Cumhuriyet University School of Medicine, Sivas, Turkey</aff>
<author-notes>
<corresp id="corresp1-1933719112452941">Gökhan Açmaz, Department of Obstetrics and Gynecology, Kayseri Training and Education Hospital of Medicine, Kayseri, Turkey Email: <email>gokhancmaz@mynet.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>20</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>32</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Blood vessels are necessary for development and maintenance of the endometriosis and blood flow supplies oxygen and essential nutrient to the disease. Local angiogenesis is regulated by vascular endothelial growth factor (VEGF) and inhibitors of VEGF may be a novel therapeutic approach. We inducted endometriosis in 43 rats and they were randomly allocated into 4 groups. The rats in group I (control n = 11) were given no medication. The rats in group II (n = 11) were given bevacizumab. The rats in group III (n = 11) were given Sorafenib, and the rats in group IV (n = 10) were given retinoic acid (RA). Then groups were compared for microvessel density, VEGF, soluble tyrosine-kinase receptor, ovarian reserve, and treatment effectivity. All these medications were effective on endometriosis and we detected that volume of endometriotic implants were significantly decreased. Ovarian reserve was not affected from the medication, in addition RA have induced reproductive capacity.</p>
</abstract>
<kwd-group>
<kwd>endometriosis</kwd>
<kwd>rat</kwd>
<kwd>treatment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Endometriosis is a serious and chronic disease, causes infertility and chronic pelvic pain, in 15% to 20% of reproductive women.<sup><xref ref-type="bibr" rid="bibr1-1933719112452941">1</xref></sup> Ectopic growth of endometrial tissue outside uterine cavity is likely connected with the inherent capability of endometrium to escape the immune surveillance and to be invasive and implanted.<sup><xref ref-type="bibr" rid="bibr2-1933719112452941">2</xref>,<xref ref-type="bibr" rid="bibr3-1933719112452941">3</xref></sup> Recently, retrograde menstruation, lymphatic or circulatory spread, genetic predisposition to the condition, immune dysfunction, and environmental causes have been suggested as being involved in its pathogenesis.<sup><xref ref-type="bibr" rid="bibr4-1933719112452941">4</xref></sup></p>
<p>Blood vessels are necessary for development and maintenance of the disease and blood flow supplies oxygen and essential nutrient to the endometriosis.<sup><xref ref-type="bibr" rid="bibr5-1933719112452941">5</xref></sup> Local angiogenesis is regulated by vascular endothelial growth factor (VEGF) and its soluble tyrosine-kinase receptor (sFLT), stimulating proliferation of vascular endothelial cells, has emerged as likely being involved in the pathogenesis of endometriosis. Peritoneal fluid and endometrial VEGF concentrations have been reported to increase in women with endometriosis.<sup><xref ref-type="bibr" rid="bibr6-1933719112452941">6</xref>,<xref ref-type="bibr" rid="bibr7-1933719112452941">7</xref></sup></p>
<p>Bevacizumab is a full-length recombinant humanized monoclonal antibody that inhibits VEGF.<sup><xref ref-type="bibr" rid="bibr8-1933719112452941">8</xref></sup> Anti-VEGF therapy with bevacizumab has demonstrated efficacy in various human malignancies.<sup><xref ref-type="bibr" rid="bibr9-1933719112452941">9</xref></sup></p>
<p>Sorafenib is one potential antiangiogenic agent.<sup><xref ref-type="bibr" rid="bibr10-1933719112452941">10</xref></sup> It is an orally active multikinase inhibitor that inhibits the tyrosine kinase activity of the VEGF receptor.<sup><xref ref-type="bibr" rid="bibr11-1933719112452941">11</xref>,<xref ref-type="bibr" rid="bibr12-1933719112452941">12</xref></sup> Phase III treatment analysis showed, sorafenib provided significant clinical benefit for patients with renal cell carcinoma.<sup><xref ref-type="bibr" rid="bibr13-1933719112452941">13</xref></sup></p>
<p>Retinoic acid (RA) is known to regulate growth and induce differentiation of normal and malignant cells, and have been used to treat cancers in which VEGF is over-expressed.<sup><xref ref-type="bibr" rid="bibr14-1933719112452941">14</xref></sup></p>
<p>As ovarian function is characterized by cells with rapid turnover there is a potential similarity to tumor cells in that both are primary targets for chemotherapeutic agents.<sup><xref ref-type="bibr" rid="bibr15-1933719112452941">15</xref></sup></p>
<p>The aim of the present study was to evaluate the efficacy of bevacizumab, sorafenib, and RA on endometriotic implants, microvessel density, VEGF, sFLT and effect of these drugs on ovarian reserve in a rat endometriosis model.</p>
<sec id="section1-1933719112452941" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>The Cumhuriyet University Committee on the Use and Care of Animals approved the experiment. A total of 48 female, 5 to 6-week–old, Wistar Albino rats weighing between 220 and 280 g provided by Cumhuriyet University Animal Reproduction Centre were used. They were caged in a controlled environment at 22°C with 12-hour light/dark cycles. Standard rat feed and water were provided ad libitum. All rats were allowed to acclimatize to this environment for 1 week before the experiment.</p>
<p>Rats were anesthetized by intraperitoneal administration of 60 mg/kg ketamine (Ketalar; Eczacibasi Warner-Lambert, Istanbul, Turkey) and 7 mg/kg xylazine (Rompun, Bayer, Istanbul, Turkey). Before surgery, the abdominal skin was shaved and antisepsis was obtained with 10% povidone iodine solution. A 7 mm segment of right uterine horn was excised after avascularization and placed in sterile phosphate-buffered saline at 37°C. Ectopic endometrium was induced surgically in rats by transplanting an autologous fragment of endometrial tissue onto the inner surface of the abdominal wall. A 5 mm diameter circular endometrial piece (surface area = 19 625 mm<sup>2</sup>) was cut by a cutting device without removing the myometrium and tissue was transplanted onto a vascular area of inner surface of the right abdominal wall with the endometrial surfaces. After the operation, all rats were observed for 14 days without medication.</p>
<sec id="section2-1933719112452941">
<title>Second Laparotomy</title>
<p>Animals underwent a second laparotomy to examine endometrial implants. During laparotomy, implant volumes were calculated in vivo by measuring their dimensions with a micrometer and using the ellipsoid volume formula (π/6 × length × width × height). There were no endometriotic foci in 3 rats and there were abscess formations in 2 rats. So these 5 rats were excluded.</p>
<p>Following the second operation, all rats were allowed a resting period of 3 days prior to random allocation to 4 groups. The rats in group I (control group, n = 11) were given no medication. The rats in group II (bevacizumab group, n = 11) were given 2.5 mg/kg bevacizumab (Avastin 25 mg/mL, Roche, Switzerland) diluted to 5 mg/mL with 9% NaCl and administered by intraperitoneal injection. This dosage was based on previous studies<sup><xref ref-type="bibr" rid="bibr16-1933719112452941">16</xref></sup> and administered again after 10 days. The rats in group III (sorafenib group, n = 11) were given 30 mg/kg per d (in 0.5 mL izotonic) oral sorafenib for 10 days. This dose was determined based on the previous study.<sup><xref ref-type="bibr" rid="bibr17-1933719112452941">17</xref></sup></p>
<p>The rats in group IV (RA group, n = 10) were given 10 mg/kg per d (in 0.5 mL olive oil) oral RA (Roaccutane, Roche) for 10 days. This dose was determined based on previous study.<sup><xref ref-type="bibr" rid="bibr18-1933719112452941">18</xref></sup></p>
<p>The oral medications were given via an orogastric tube by laboratory personnel. All the rats were observed for 8 days. After the randomization, 2 rats in sorefenib and 1 rat in RA group died and a rat which developed an abscess in each sorafenib and bevacizumab group were also excluded from the study.</p>
</sec>
<sec id="section3-1933719112452941">
<title>Third Laparotomy</title>
<p>After the end of the medical treatment, rats were euthanized by ketamine, and then third laparotomy was performed. During laparotomy, implant volumes were calculated again. The implants and both ovaries were excised and fixed in 10% formalin for histopathological examination. All operations and measurements were performed by physicians blinded to the groups.</p>
</sec>
<sec id="section4-1933719112452941">
<title>Histopathological Examination</title>
<sec id="section5-1933719112452941">
<title>Evaluation of endometriosis</title>
<p>Samples from the endometriosis areas were fixed in 10% formalin for a minimum of 12 hours. After routine procedures, specimens were embedded in paraffin and cut into 5 μm sections. Sections were stained with hematoxylin and eosin (H&amp;E) and examined under a light microscope. The persistence of epithelial cells in endometrial implants was evaluated semiquantitatively as follows: 3: well-preserved epithelial layer, 2: moderately preserved epithelium with leukocyte infiltrate, 1: poorly preserved epithelium (occasional epithelial cells only); and 0: no epithelium. This evaluation was based on a previous rat endometriosis study.<sup><xref ref-type="bibr" rid="bibr19-1933719112452941">19</xref></sup></p>
</sec>
<sec id="section6-1933719112452941">
<title>Immunohistochemistry</title>
<p>Sections were deparaffinized in xylene and dehydrated through graded concentrations of ethanol. After blocking of endogenous peroxidase activity with 3% hydrogen peroxide for 15 minutes, the sections were heated in 0.01 mol/L of citrate buffer in a microwave pressure cooker for 20 minutes. The slides were allowed to cool to room temperature, and nonspecific binding was blocked with normal horse serum for 20 minutes at room temperature. The sections were further incubated with the primary antibody against CD31 (Rabbit Polyclonal, Cat.#RB-10333-R7 Thermo Scientific, USA), CD105 (Mouse monoclonal, clone HZ52 Neomarkers, USA), VEGF (Mouse monoclonal, Clone 2D2, Neomarkers), and sFLT (Mouse monoclonal Clone 8C8, Neomarkers) were applied for 30 minutes. The sections were then stained using avidin–biotin complex (ABC) by immunoperoxidase technique employing commercially available reagent (ABC kit, Labvision, USA), for demonstration of binding sites, then AEC chromogen was applied. Phosphate-buffered saline was used for rinsing after each step and finally all sections were counterstained with Mayer hematoxylin.</p>
</sec>
<sec id="section7-1933719112452941">
<title>Evaluation of immunostaining</title>
<p>Microvessel density was determined by counting the number of CD31- and CD105-positive microvessels in an entire 1-mm core. A microvessel was defined as any endothelial cell or endothelial cell cluster staining positive for CD31 and CD105.</p>
<p>A semiquantitative evaluation of immunohistochemical staining for VEGF and sFLT was performed according to the method described by Donnez et al.<sup><xref ref-type="bibr" rid="bibr6-1933719112452941">6</xref></sup> The histologic scores (<italic>H</italic>) for VEGF and sFLT were calculated using formula <italic>H</italic> = ∑<italic>Pi</italic>, where <italic>i</italic> is the intensity ranging from 0 (negative cells) to 3 (intensely stained cells), and <italic>P</italic> is the percentage of stained cells for each given <italic>i,</italic> with <italic>P</italic> values of 1, 2, 3, 4, and 5 indicating &lt;15%, 15% to 50%, 50% to 85%, &gt;85%, and 100% positive-staining cells, respectively. All tissues were evaluated by the same pathologist (H.Ö.), who was blinded to the origin of the samples.</p>
</sec>
<sec id="section8-1933719112452941">
<title>Evaluation of ovarian reserve</title>
<p>Both ovaries were fixed in 10% formalin and embedded in paraffin. Serial sections were prepared and stained with H&amp;E to determine the number of primordial follicles. Two specimens were inadequate for histologic sections in the control group. Primordial follicles were identified by the presence of oocytes encapsulated partially or completely by a single layer of flattened follicle cells without a theca layer. The primordial follicles (or unilaminar follicles) are located near the outer surface of the ovary and distinguished by a single layer of flattened follicle cells. Assessment of ovarian toxicity by follicle quantification of serial sections is time-consuming, expensive and primordial follicle toxicity is adequately defined by counting 5 random sections.<sup><xref ref-type="bibr" rid="bibr20-1933719112452941">20</xref></sup> The sections were counted from both ovaries of the rats.</p>
</sec>
</sec>
<sec id="section9-1933719112452941">
<title>Statistical Analysis</title>
<p>To test the normality and variance homogeneity assumption of the data, Shapiro-Wilk and Levene tests were used, respectively. Values are expressed as mean ± standard deviation or median (25th percentile-75th percentile). Paired <italic>t</italic> test was used to compare the volumes of endometrial implants in rats before and after treatment for each group. One-way analysis of variance (ANOVA) and Kruskal-Wallis test were performed for the comparison of differences between groups. Brown-Forsythe test was used instead of one-way ANOVA when the variance homogeneity assumption did not hold. Tukey and Siegel-Castellan post hoc tests were used for the multiple comparisons. All analysis were performed using Statistica software (version 7.0, SPSS Inc., Chicago, Illinois) considering the significance level of .05.</p>
</sec>
</sec>
<sec id="section10-1933719112452941">
<title>Results</title>
<p>There were no differences among the groups for endometriosis score at the beginning of the study. Bevacizumab was the most effective medication on VEGF (<xref ref-type="fig" rid="fig1-1933719112452941">Figure 1A</xref> and B) and significantly reduced the volume of endometriotic implants. Sorafenib not only decreased sFLT and microvessel density significantly (<xref ref-type="fig" rid="fig1-1933719112452941">Figure 1C</xref>-F) but also it was effective on VEGF and implants volume.</p>
<fig id="fig1-1933719112452941" position="float">
<label>Figure 1.</label>
<caption>
<p>Immunostaining (A and B) VEGF staining. A, Strong glandular, stromal, and endothelial staining in RA group. B, Moderate stroma staining and weak glandular and endothelial staining in bevacizumab group. sFLT staining (C) strong glandular, stromal, and endothelial staining in RA group. D, Weak glandular and stromal staining in sorafenib group. Microvessel density (E) high microvessel density with CD31 staining in RA group. F, Low microvessel density with CD31 staining in sorafenib group (IHC; ×200). g indicates glandular area s: stromal area; IHC, immunohistochemistry; RA, retinoic acid; sFLT, soluble tyrosine-kinase receptor; VEGF, vascular endothelial growth factor.</p>
</caption>
<graphic xlink:href="10.1177_1933719112452941-fig1.tif"/>
</fig>
<p>Retinoic acid was not found to be effective on VEGF, sFLT, and microvessel density; however, RA was the most effective medication for endometriotic implants (<xref ref-type="fig" rid="fig2-1933719112452941">Figure 2</xref>).</p>
<fig id="fig2-1933719112452941" position="float">
<label>Figure 2.</label>
<caption>
<p>Appearances of the endometriosis foci. A, Appearance of endometriosis foci before treatment. B, Appearance of endometriosis foci after RA administration. RA indicates retinoic acid.</p>
</caption>
<graphic xlink:href="10.1177_1933719112452941-fig2.tif"/>
</fig>
<p>Comparison of groups for microvessel density, VEGF, sFLT, ovarian reserve, and endometrial implants volume is shown in <xref ref-type="table" rid="table1-1933719112452941">Table 1</xref>.</p>
<table-wrap id="table1-1933719112452941" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of Groups for Microvessel Density, VEGF, sFLT, Ovarian Reserve, and Treatment Effectivity<sup>a</sup></p>
</caption>
<graphic alternate-form-of="table1-1933719112452941" xlink:href="10.1177_1933719112452941-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Control (n = 11)</th>
<th>Bevacizumab (n = 10)</th>
<th>Sorafenib (n = 8)</th>
<th>Retinoic Acid (n = 9)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endometriosis score</td>
<td>2.00 (2.00-3.00)</td>
<td>2.00 (0.00-2.00)</td>
<td>1.00 (0.00-2.75)</td>
<td>2.00 (1.00-3.00)</td>
<td>.145</td>
</tr>
<tr>
<td>CD31</td>
<td>21.82 ± 6.34<sup>c</sup>
</td>
<td>16.60 ± 3.63<sup>c,d</sup>
</td>
<td>12.75 ± 3.65<sup>d</sup>
</td>
<td>17.44 ± 5.32<sup>c,d</sup>
</td>
<td>.004</td>
</tr>
<tr>
<td>CD105</td>
<td>20.82 ± 6.43<sup>c</sup>
</td>
<td>16.30 ± 2.98<sup>c,d</sup>
</td>
<td>11.38 ± 3.29<sup>d</sup>
</td>
<td>15.89 ± 5.37<sup>c,d</sup>
</td>
<td>.002</td>
</tr>
<tr>
<td>VEGF</td>
<td>9.00 (4.00-12.00)<sup>c</sup>
</td>
<td>2.00 (1.00-6.50)<sup>d</sup>
</td>
<td>2.50 (0.00-4.75)<sup>d</sup>
</td>
<td>6.00 (5.00-8.50)<sup>c,d</sup>
</td>
<td>.002</td>
</tr>
<tr>
<td>sFLT</td>
<td>12.00 (11.00-13.00)<sup>c</sup>
</td>
<td>3.50 (2.75-11.50)<sup>c,d</sup>
</td>
<td>2.50 (0.50-4.50)<sup>d</sup>
</td>
<td>10.00 (7.50-12.00)<sup>c,d</sup>
</td>
<td>.005</td>
</tr>
<tr>
<td>Ovarian reserve</td>
<td>3.00 (3.00-7.00)<sup>c,d</sup>
</td>
<td>2.50 (1.00-4.00)<sup>c,d</sup>
</td>
<td>1.50 (1.00-2.75)<sup>c</sup>
</td>
<td>5.00 (2.50-7.50)<sup>d</sup>
</td>
<td>.012</td>
</tr>
<tr>
<td colspan="6">Volume</td>
</tr>
<tr>
<td> Before</td>
<td>44.20 ± 17.04</td>
<td>38.47 ± 16.34</td>
<td>40.76 ± 20.10</td>
<td>40.83 ± 14.32</td>
<td>.893</td>
</tr>
<tr>
<td> After</td>
<td>47.30 ± 18.78<sup>c</sup>
</td>
<td>27.32 ± 9.40<sup>d</sup>
</td>
<td>31.13 ± 13.17<sup>c,d</sup>
</td>
<td>28.11 ± 11.86<sup>c,d</sup>
</td>
<td>.007</td>
</tr>
<tr>
<td> Δ volume</td>
<td>3.10 ± 6.35<sup>c</sup>
</td>
<td>−11.15 ± 10.22<sup>d</sup>
</td>
<td>−9.64 ± 11.94<sup>d</sup>
</td>
<td>−12.72 ± 7.58<sup>d</sup>
</td>
<td>.001</td>
</tr>
<tr>
<td>
<italic>P</italic> Value<sup>b</sup>
</td>
<td align="center">.136</td>
<td align="center">.007</td>
<td align="center">.056</td>
<td align="center">.001</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1933719112452941">
<p>Abbreviations: sFLT, soluble tyrosine-kinase receptor; VEGF, vascular endothelial growth factor.</p>
</fn>
<fn id="table-fn2-1933719112452941">
<p>
<sup>a</sup> Values are expressed as mean ± SD or median (25th percentile-75th percentile). Different superscripts in a row indicate significant differences between the groups.</p>
</fn>
<fn id="table-fn3-1933719112452941">
<p>
<sup>b</sup> Comparison of volume values before and after treatment.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We did not detect any difference for ovarian reserve among the groups, except for RA group. Ovarian reserve was significantly higher in RA group than others (<xref ref-type="fig" rid="fig3-1933719112452941">Figure 3</xref>).</p>
<fig id="fig3-1933719112452941" position="float">
<label>Figure 3. Evaluation.</label>
<caption>
<p>Evaluation of primordial follicles. The asterisks indicate primordial follicles. A, Sorafenib group; B, RA group (H&amp;E ×400). H&amp;E indicates hematoxylin and eosin; RA, retinoic acid.</p>
</caption>
<graphic xlink:href="10.1177_1933719112452941-fig3.tif"/>
</fig>
</sec>
<sec id="section11-1933719112452941">
<title>Discussion</title>
<p>The autotransplantation of uterine pieces into the peritoneal cavity is a well-known method for the induction of endometriosis in rats and these implants are similar to human lesions in vivo. They react in a similar manner to human endometriotic tissues and cells in isolated cell cultures. Therefore, this model permits the examination of novel therapeutic approaches for endometriosis.<sup><xref ref-type="bibr" rid="bibr21-1933719112452941">21</xref></sup></p>
<p>Traditional medical treatments for endometriosis are usually aimed to decrease endogenous steroid production. Although they are effective in reducing the size of endometriosis and pain related symptoms, their adverse effects limit their long-term use, and recurrence rates after cessation of therapy are high. Additionally, they have no benefit for endometriosis-associated infertility.<sup><xref ref-type="bibr" rid="bibr22-1933719112452941">22</xref></sup></p>
<p>For these reasons, endometriosis treatment needs new approaches which might be effective on lesions by different mechanisms such as new vessel formation. Angiogenesis is essential for the pathogenesis of many diseases such as cancer, atherosclerosis, and endometriosis.<sup><xref ref-type="bibr" rid="bibr23-1933719112452941">23</xref></sup> It has been shown that endometriotic lesions are highly vascularized and it is widely accepted that angiogenesis is critical for their establishment and growth in ectopic sites.<sup><xref ref-type="bibr" rid="bibr5-1933719112452941">5</xref></sup> Thus, the suppression of blood vessel development by inhibition of VEGF may be a novel therapeutic approach for the treatment of endometriosis.<sup><xref ref-type="bibr" rid="bibr24-1933719112452941">24</xref></sup> In a study, Becker et al revealed that treatment of endometriotic lesions with antiangiogenic drugs do not affect estrous cycling, corpus luteum formation, serum hormone levels, and mating time as fertility measures; and pregnancy rates, length of pregnancy, fetal vitality, number, and outcome of litter as reproductive measures.<sup><xref ref-type="bibr" rid="bibr25-1933719112452941">25</xref></sup></p>
<p>In this study, following the administration of bevacizumab, sFLT and VEGF decreased in the endometriotic surfaces and reduced microvessel density was detected as well. Bevacizumab was the most effective drug on VEGF which may have accompanied the reduction in endometriotic volume. Therefore, bevacizumab lowers the size of endometriosis by inhibition of VEGF and it did not have effect on ovarian reserve. In literature, bevacizumab inhibits corneal neovascularization,<sup><xref ref-type="bibr" rid="bibr26-1933719112452941">26</xref></sup> increases apoptosis, and decreases cell proliferation in endometrial implant.<sup><xref ref-type="bibr" rid="bibr27-1933719112452941">27</xref></sup></p>
<p>In sorafenib group, we detected decreased sFLT, VEGF which was also associated with reduced endometriotic volumes. In addition, we demonstrated an antiangiogenic effect of sorafenib, as verified by the reduction of microvessel density in endometrial implants. The effect of angiostatic agents on endometriotic implants has been demonstrated by Hull et al. They concluded that antiangiogenic agents inhibit the growth of implants by disrupting the vascular supply. Park et al showed that VEGF receptor blockage in monkeys resulted in inhibition of endometriosis.<sup><xref ref-type="bibr" rid="bibr24-1933719112452941">24</xref>,<xref ref-type="bibr" rid="bibr28-1933719112452941">28</xref></sup></p>
<p>Retinoic acid did not have any effect on sFLT, VEGF, and angiogenesis; however, volume of endometriotic implants was significantly decreased (<xref ref-type="fig" rid="fig2-1933719112452941">Figure 2</xref>); additionally, we detected that ovarian reserve was significantly high in this group. Pavone et al illustrated decreased retinoid uptake in endometrial stromal cells which contribute to a resistance to apoptosis in endometriosis.<sup><xref ref-type="bibr" rid="bibr29-1933719112452941">29</xref></sup> Additionally, Moraloglu et al illustrated that antiangiogenic agent decrease the adhesion formation so it can be concluded that antiangiogenic agents may have beneficial effect on infertility.<sup><xref ref-type="bibr" rid="bibr30-1933719112452941">30</xref></sup></p>
<p>Our results are in agreement with the literature. Because of antiangiogenic effect of bevacuzimab and sorafenib, we were not able to illustrate this effect for RA. On the other hand, RA was the most effective agent in reduction of endometrial implants.</p>
<p>Tee et al showed that RA inhibits VEGF in HL-60 cells, which are accepted neutrophil-like cells in endometrium.<sup><xref ref-type="bibr" rid="bibr31-1933719112452941">31</xref></sup> Neutrophil granulocytes within the endometrium are a rich source of VEGF,<sup><xref ref-type="bibr" rid="bibr32-1933719112452941">32</xref></sup> and this observation has been independently confirmed by others.<sup><xref ref-type="bibr" rid="bibr33-1933719112452941">33</xref></sup> So we are of the opinion that RA inhibits VEGF in the neutrophil-like cells, not in the tissue. This is why we did not detect this finding in our study. The anti-inflammatory effect of RA is proved from treatment of skin disease and plausible explanation of this property depends on inhibition of nuclear factor κB or modulation of expression of interleukins.<sup><xref ref-type="bibr" rid="bibr34-1933719112452941">34</xref></sup> Additionally, antiproliferative actions of RA include more than 1 pathway; these are inhibition of activator protein 1, cyclin 1 and stimulation of protein p21 which are accepted inhibitors of cell cycle.<sup><xref ref-type="bibr" rid="bibr35-1933719112452941">35</xref></sup></p>
<p>Niikura et al illustrated that ovarian reserve and primordial follicles can be increased by RA-gene-8 and this occurs without changes in follicle growth activation or atresia.<sup><xref ref-type="bibr" rid="bibr36-1933719112452941">36</xref></sup> It can be concluded that traditional medications of endometriosis have no benefit on endometriosis-associated infertility; however, RA may activate reproductive capacity of patient with endometriosis and RA can be accepted as antiaging agent in the treatment of endometriosis.</p>
<p>We focused on antiangiogenic properties of these agents, however, we did not evaluate apoptosis, antiproliferative actions, and inflammation markers in endometriotic implants, and these are potential limitations of this study. We are able to show that these agents were effective on endometriosis and ovarian reserve was not affected from the medication; in addition, RAs have induced reproductive capacity. Currently, the use of these medications in a clinical setting has been limited secondary to potential teratogenicity as well as toxicity. However, agents that target the specific receptors of endometriosis may prove to be useful therapeutic targets in the future, bypassing the toxicity and teratogenicity encountered with these drugs.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank Dr Faruk Balkaya (English Department of Kayseri Erciyes University) for his contribution to English terms and language.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1933719112452941"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1933719112452941"><label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Cumhuriyet University financially supported this study.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719112452941">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodgers</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>D’Hooghe</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Fazleabas</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Priorities for endometriosis research: recommendation from an international consensus workshop</article-title>. <source>Reprod Sci</source>. <year>2009</year>;<volume>16</volume>(<issue>4</issue>):<fpage>335</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr2-1933719112452941">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bondza</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Mahenx</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Akoum</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Insights into endometriosis-associated endometrial dysfunctions: a review</article-title>. <source>Front Biosci (Elite Ed)</source>. <year>2009</year>;<volume>1</volume>:<fpage>415</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr3-1933719112452941">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nap</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Groothuis</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Evers</surname>
<given-names>JLH</given-names>
</name>
<name>
<surname>Dunselman</surname>
<given-names>GAJ</given-names>
</name>
</person-group>. <article-title>Pathogenesis of endometriosis</article-title>. <source>Best Pract Res Clin Obstet Gynecol</source>. <year>2004</year>;<volume>18</volume>(<issue>2</issue>):<fpage>233</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr4-1933719112452941">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braundmeier</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Fazleabas</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Lessey</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toole</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium</article-title>. <source>J Clin Endocrin Metab</source>. <year>2006</year>;<volume>91</volume>(<issue>6</issue>):<fpage>2358</fpage>–<lpage>2365</lpage>.</citation>
</ref>
<ref id="bibr5-1933719112452941">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groothuis</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Nap</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Winterhager</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grümmer</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Vascular development in endometriosis</article-title>. <source>Angiogenesis</source>. <year>2005</year>;<volume>8</volume>(<issue>2</issue>):<fpage>147</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr6-1933719112452941">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donnez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Smoes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gillerot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Casanas-Roux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nisolle</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Vascular endothelial growth factor (VEGF) in endometriosis</article-title>. <source>Hum Reprod</source>. <year>1998</year>;<volume>13</volume>(<issue>6</issue>):<fpage>1686</fpage>–<lpage>1690</lpage>.</citation>
</ref>
<ref id="bibr7-1933719112452941">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLaren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Charnock-Jones</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>SK</given-names>
</name>
</person-group>. <article-title>Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis</article-title>. <source>Hum Reprod</source>. <year>1996</year>;<volume>11</volume>(<issue>1</issue>):<fpage>220</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr8-1933719112452941">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurwitz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fehrenbacher</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Novotny</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>(<issue>23</issue>):<fpage>2335</fpage>–<lpage>2342</lpage>.</citation>
</ref>
<ref id="bibr9-1933719112452941">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grothey</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>LM</given-names>
</name>
</person-group>. <article-title>Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies</article-title>. <source>Cancer J</source>. <year>2008</year>;<volume>14</volume>(<issue>3</issue>):<fpage>170</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr10-1933719112452941">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young-Hoon</surname>
<given-names>Park</given-names></name>
<name>
<surname>Roh</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YC.</given-names>
</name>
</person-group> <article-title>Effect of sorafenib on experimental choroidal neovascularization in the rat</article-title>. <source>Clin Exp Ophthalmol</source>. <year>2010</year>;<volume>38</volume>(<issue>7</issue>):<fpage>718</fpage>–<lpage>726</lpage>.</citation>
</ref>
<ref id="bibr11-1933719112452941">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adnane</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Trail</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>Sorafenib (BAY 43–9006, Nexavar<sup>®</sup>), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature</article-title>. <source>Methods Enzymol</source>. <year>2006</year>;<volume>407</volume>:<fpage>597</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr12-1933719112452941">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilhelm</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>:<fpage>7099</fpage>–<lpage>7109</lpage>.</citation>
</ref>
<ref id="bibr13-1933719112452941">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Escudier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>WM</given-names>
</name>
<etal/>
</person-group> <article-title>Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>20</issue>):<fpage>3312</fpage>–<lpage>3318</lpage>.</citation>
</ref>
<ref id="bibr14-1933719112452941">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tee</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Vigne</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
</person-group>. <article-title>All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>3</issue>):<fpage>1264</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr15-1933719112452941">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yucebilgin</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Terek</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Ozsaran</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility</article-title> <source>Aust N Z J Obstet Gynaecol</source>. <year>2004</year>;<volume>44</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr16-1933719112452941">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basbug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bulbuller</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Camci</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>The effect of antivascular endothelial growth factor on the development of adhesion formation in laparotomized rats: experimental study</article-title>. <source>Gastroenterol Res Pract</source>. <year>2011</year>;<volume>2011</volume>:<fpage>578691</fpage>.</citation>
</ref>
<ref id="bibr17-1933719112452941">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YC</given-names>
</name>
</person-group>. <article-title>Effect of sorafenib on experimental choroidal neovascularization in the rat</article-title>. <source>Clin Experiment Ophthalmol</source>. <year>2010</year>;<volume>38</volume>(<issue>7</issue>):<fpage>718</fpage>–<lpage>726</lpage>.</citation>
</ref>
<ref id="bibr18-1933719112452941">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Dwyer</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ravikumar</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>G</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Effect of 13-cis-retinoic acid on tumor prevention, tumor growth, and metastasis in experimental colon cancer</article-title>. <source>J Surg Res</source>. <year>1987</year>;<volume>43</volume>(<issue>6</issue>):<fpage>550</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr19-1933719112452941">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keenan</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Williams-Boyce</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Caudle</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Bukovsky</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole</article-title>. <source>Fertil Steril</source>. <year>1999</year>;<volume>72</volume>(<issue>1</issue>):<fpage>135</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr20-1933719112452941">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Plowchalk</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Sipes</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Mattison</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Comparison of random and serial sections in assessment of ovarian toxicity</article-title>. <source>Reprod Toxicol</source>. <year>1991</year>;<volume>5</volume>(<issue>4</issue>):<fpage>379</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr21-1933719112452941">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharpe-Timms</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Using rats as a research model for the study of endometrosis</article-title>. <source>Ann N Y Acad Sci</source>. <year>2002</year>;<volume>955</volume>:<fpage>318</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr22-1933719112452941">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fedorkow</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vandekerckhove</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Ovulation suppression for endometriosis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2000</year>;(<volume>2</volume>):<fpage>CD000155</fpage>.</citation>
</ref>
<ref id="bibr23-1933719112452941">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffioen</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Molema</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation</article-title>. <source>Pharmacol Rev</source>. <year>2000</year>;<volume>52</volume>(<issue>2</issue>):<fpage>237</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr24-1933719112452941">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hull</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Charnock-Jones</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CL</given-names>
</name>
<etal/>
</person-group> <article-title>Antiangiogenic agents are effective inhibitors of endometriosis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>(<issue>6</issue>):<fpage>2889</fpage>–<lpage>2899</lpage>.</citation>
</ref>
<ref id="bibr25-1933719112452941">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rupnick</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group> <article-title>Endostatin inhibits the growth of endometriotic lesions but does not affect fertility</article-title>. <source>Fertil Steril</source>. <year>2005</year>;<volume>84</volume>(<issue>suppl 2</issue>):<fpage>1144</fpage>–<lpage>1155</lpage>.</citation>
</ref>
<ref id="bibr26-1933719112452941">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papathanassiou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Theodossiadis</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Liarakos</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Rouvas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Giamarellos-Bourboulis</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Vergados</surname>
<given-names>IA</given-names>
</name>
</person-group>. <article-title>Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model</article-title>. <source>Am J Ophthalmol</source>. <year>2008</year>;<volume>145</volume>(<issue>3</issue>):<fpage>424</fpage>–<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr27-1933719112452941">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricci</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Olivares</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Bilotas</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Meresman</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Barañao</surname>
<given-names>RI</given-names>
</name>
</person-group>. <article-title>Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis</article-title>. <source>Reprod Sci</source>. <year>2011</year>;<volume>18</volume>(<issue>7</issue>):<fpage>614</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr28-1933719112452941">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>ACP</given-names>
</name>
<name>
<surname>Ferin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zeitoun</surname>
<given-names>K.</given-names>
</name>
</person-group> <article-title>Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor: a novel treatment for endometriosis</article-title>. <source>Fertil Steril</source>. <year>2004</year>;<volume>82:71</volume>.</citation>
</ref>
<ref id="bibr29-1933719112452941">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavone</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Reierstad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Milad</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bulun</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>YH</given-names>
</name>
</person-group>. <article-title>Altered retinoid uptake and action contributes to cell survival in endometriosis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2010</year>;<volume>95</volume>(<issue>11</issue>):<fpage>E300</fpage>–<lpage>E309</lpage>.</citation>
</ref>
<ref id="bibr30-1933719112452941">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moraloglu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Isik</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kilic</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity</article-title>. <source>Fertil Steril</source>. <year>2011</year>;<volume>95</volume>(<issue>8</issue>):<fpage>2638</fpage>–<lpage>2641</lpage>.</citation>
</ref>
<ref id="bibr31-1933719112452941">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tee</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Vigne</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
</person-group>. <article-title>All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>3</issue>):<fpage>1264</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr32-1933719112452941">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Lebovic</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Garrett</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
</person-group>. <article-title>Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis</article-title>. <source>Fertil Steril</source>. <year>2000</year>;<volume>74</volume>(<issue>1</issue>):<fpage>107</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr33-1933719112452941">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gargett</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Heryanto</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gambino</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils</article-title>. <source>Hum Reprod</source>. <year>2001</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1065</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr34-1933719112452941">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Na</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>BY</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NF kB</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>(<issue>12</issue>):<fpage>7674</fpage>–<lpage>7680</lpage>.</citation>
</ref>
<ref id="bibr35-1933719112452941">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bollag</surname> <given-names>W</given-names>
</name>
<name>
<surname>Majewski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jablonska</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Cancer combination chemotherapy with retinoids: experimental rationale</article-title>. <source>Leukemia</source>. <year>1994</year>;<volume>8</volume>(<issue>9</issue>):<fpage>1453</fpage>–<lpage>1457</lpage>.</citation>
</ref>
<ref id="bibr36-1933719112452941">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niikura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niikura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Satirapod</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tilly</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Systemic signals in aged males exert potent rejuvenating effects on the ovarian follicle reserve in mammalian females</article-title>. <source>Aging (Albany NY)</source>. <year>2010</year>;<volume>2</volume>(<issue>12</issue>):<fpage>999</fpage>–<lpage>1003</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>